Skip to main content

Table 3 Data from 14 articles that externally validated 32 existing prognostic models for HCC patients undergoing systemic therapy

From: Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal

Model

c-statistics

95%CI lower

95%CI upper

Outcome

Type of cohort(N)

events(n)

PROSASH-II

0.65

NA

NA

NA

Training (615)

559

0.68

0.65

0.72

OS

Validation (290)

273

0.63

0.6

0.65

OS

Validation (552)

NA

PROSASH

0.72

0.69

0.75

OS

Training (500)

NA

0.7

0.67

0.73

OS

Validation (421)

0.71

0.69

0.73

OS

All(500 + 421)

0.63

0.6

0.66

OS

Validation (438)

NA

ALBI

0.6

NA

NA

NA

Validation (905)

NA

0.595

0.566

0.625

OS

Validation (468)

NA

0.56

0.51

0.6

OS

Validation (681)

NA

0.59

NA

NA

NA

Validation (615)

559

0.62

0.58

0.65

NA

Validation (290)

273

0.53

0.51

0.56

OS

Validation (552)

NA

0.638

0.599

0.676

OS

Validation (900)

598

0.748

0.732

0.763

OS

Validation (3182)

NA

Child–Pugh

0.61

NA

NA

NA

Validation (905)

NA

0.53

NA

NA

NA

Validation (615)

559

0.58

0.55

0.61

OS

Validation (290)

273

0.584

0.539

0.629

FFS

Validation (201)

155

0.592

0.547

0.637

OS

Validation (201)

155

0.52

0.51

0.54

OS

Validation (552)

NA

0.638

0.598

0.678

OS

Validation (900)

598

BCLC

0.637

0.58

0.695

OS

Validation (435)

NA

0.55

0.528

0.571

OS

Validation (468)

NA

0.56

0.52

0.6

OS

Validation (681)

NA

0.54

NA

NA

NA

Validation (615)

559

0.57

NA

NA

NA

Validation (290)

273

0.57

0.55

0.6

OS

Validation (552)

NA

0.65

NA

NA

OS

Validation (3628)

NA

0.64

NA

NA

OS

Validation (1555)

NA

0.73

NA

NA

OS

Validation (2651)

NA

0.739

0.709

0.769

OS

Validation (1013)

NA

0.678

0.559

0.796

OS

Validation (108)

NA

0.665

0.653

0.678

OS

Validation (1969)

NA

0.71

0.67

0.74

OS

Validation (904)

508

0.727

0.692

0.762

OS

Validation (900)

598

0.807

0.773

0.824

OS

Validation (1188)

652

HAP

0.653

0.624

0.681

OS

Validation (468)

NA

0.6

NA

NA

NA

Validation (615)

559

0.67

0.64

0.7

OS

Validation (290)

273

0.59

0.56

0.62

OS

Validation (552)

NA

SAP

0.64

0.614

0.667

OS

Validation (468)

NA

0.6

NA

NA

NA

Validation (615)

559

0.69

0.66

0.72

OS

Validation (290)

273

0.58

0.55

0.61

OS

Validation (552)

NA

JIS

0.691

0.638

0.744

OS

Validation (435)

NA

0.55

NA

NA

OS

Validation (615)

559

0.59

0.55

0.62

OS

Validation (290)

273

0.67

NA

NA

OS

Validation (3628)

NA

0.67

NA

NA

OS

Validation (1555)

NA

0.7

NA

NA

OS

Validation (2651)

NA

0.753

0.748

0.771

OS

Validation (1969)

NA

0.7

0.66

0.73

OS

Validation (477)

295

0.78

0.76

0.8

OS

Validation (904)

508

0.798

0.774

0.823

OS

Validation (1188)

652

CLIP

0.542

0.485

0.599

OS

Validation (435)

NA

0.66

0.6

0.72

OS

Validation (681)

NA

0.642

0.604

0.68

FFS

Validation (201)

155

0.642

0.605

0.679

OS

Validation (201)

155

0.69

NA

NA

OS

Validation (3628)

NA

0.68

NA

NA

OS

Validation (1555)

NA

0.75

NA

NA

OS

Validation (2651)

NA

0.76

0.748

0.771

OS

Validation (1969)

NA

0.7

0.66

0.74

OS

Validation (477)

295

0.75

0.73

0.77

OS

Validation (904)

508

0.777

0.744

0.809

OS

Validation (900)

598

0.75

0.727

0.774

OS

Validation (1188)

652

Okuda

0.632

0.577

0.687

OS

Validation (435)

NA

0.64

0.6

0.69

OS

Validation (681)

NA

0.639

0.601

0.676

FFS

Validation (201)

155

0.68

0.641

0.718

OS

Validation (201)

155

0.733

0.718

0.748

OS

Validation (1973)

NA

JRC

0.755

0.707

0.803

OS

Training (435)

NA

AJCC TNM7

0.56

0.5

0.62

OS

Validation (681)

NA

0.755

0.724

0.785

OS

Validation (1013)

NA

0.741

0.635

0.847

OS

Validation (108)

NA

0.675

0.659

0.691

OS

Validation (1973)

NA

SCHCC

0.818

NA

NA

OS

Training (612)

NA

MESIAH

0.77

0.74

0.8

OS

Training (477)

295

0.82

0.8

0.83

OS

Validation (904)

508

0.69

NA

NA

OS

Validation (3628)

NA

0.69

NA

NA

OS

Validation (1555)

NA

0.77

NA

NA

OS

Validation (2651)

NA

0.835

0.81

0.861

OS

Validation (1013)

NA

0.785

0.687

0.884

OS

Validation (108)

NA

0.792

0.782

0.803

OS

Validation (1969)

NA

Modified BCLC

0.66

NA

NA

OS

Validation (3628)

NA

0.66

NA

NA

OS

Validation (1555)

NA

0.75

NA

NA

OS

Validation (2651)

NA

HKLC

0.68

NA

NA

OS

Validation (3628)

NA

0.68

NA

NA

OS

Validation (1555)

NA

0.75

NA

NA

OS

Validation (2651)

NA

ITA.LA.CA

0.57

0.54

0.59

OS

Validation (552)

NA

0.72

NA

NA

OS

Training (3628)

NA

0.71

NA

NA

OS

Validation (1555)

NA

0.78

NA

NA

OS

Validation (2651)

NA

Tokyo score

0.716

0.703

0.729

OS

Validation (1969)

NA

0.702

0.685

0.719

OS

Validation (1973)

NA

0.767

0.742

0.793

OS

Validation (1188)

652

APRI

0.569

0.53

0.608

OS

Validation (900)

598

PALBI

0.67

0.632

0.707

OS

Validation (900)

598

0.78

0.765

0.794

OS

Validation (3182)

NA

FIB-4 score

0.540

0.5

0.579

OS

Validation (900)

598

MELD

0.591

0.551

0.631

OS

Validation (900)

598

0.664

0.647

0.68

OS

Validation (3182)

NA

CTP

0.742

0.727

0.757

OS

Validation (3182)

NA

CP-based BCLC

0.757

0.741

0.774

OS

Validation (1973)

NA

ALBI-based BCLC

0.76

0.743

0.776

OS

Validation (1973)

NA

CP-CLIP

0.785

0.769

0.802

OS

Validation (1973)

NA

ALBI-CLIP

0.789

0.772

0.806

OS

Validation (1973)

NA

ALBI-based JIS (ALBI-T)

0.74

0.723

0.757

OS

Validation (1973)

NA

LCSGJ TNM

0.686

0.67

0.703

OS

Validation (1973)

NA

CUPI

0.708

0.696

0.72

OS

Validation (1973)

NA

0.701

0.679

0.722

OS

Validation (1188)

652

CP-based JIS

0.734

0.717

0.751

OS

Validation (1973)

NA

GRETCH

0.688

0.664

0.713

OS

Validation (1188)

652

  1. AJCC TNM American Joint Committee on Cancer Tumour Node Metastasis, FFS Failure-free survival, ALBI Albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, CLIP Cancer of the Liver Italian Program score, HAP Hepatoma arterial-embolization prognostic score, JIS Japan Integrated Staging score, JRC Japan Red Cross score, MESIAH Model to Estimate Survival in Ambulatory HCC patients, PROSASH Prediction Of Survival in Advanced Sorafenib-treated HCC, SAP Sorafenib Advanced HCC Prognostic score, APRI Aspartate aminotransferase-to-platelet ratio index, PALBI Platelet-albumin-bilirubin index, FIB-4 score Fibrosis-4, MELD Model for end-stage liver disease score, CTP Child–Turcotte–Pugh, CUPI Chinese University Prognostic Index, LCSGJ Liver Cancer Study Group of Japan, GRETCH Groupe d’Etude du Treatment du Carcinome H′epatocellulaire